Gilead's HIV drug shows potential in two mid-stage studies

September 24, 2014 2:21 PM

19 0

Sept 24 (Reuters) - Gilead Sciences Inc said its HIV tablet containing tenofovir alafenamide was found better than its approved drug, Stribild, in two mid-stage studies.

The company's shares rose 1.3 percent to $106.77 in early trading on the Nasdaq on Wednesday.

Read more

To category page